Apr 28, 2026 07:29AM Sensei Biotherapeutics (SNSE) files for 24.87M share offering by selling stockholders

Apr 20, 2026 06:19AM Leerink Partners Starts Sensei Biotherapeutics (SNSE) at Outperform

Feb 25, 2026 06:01AM Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 18, 2026 07:57AM Sensei Biotherapeutics (SNSE) Halted, News Pending

Nov 14, 2025 07:59AM Sensei Biotherapeutics (SNSE) Misses Q3 EPS by 362c

Nov 14, 2025 07:59AM Sensei Biotherapeutics (SNSE) Misses Q3 EPS by 362c

Oct 30, 2025 10:58AM H.C. Wainwright Downgrades Sensei Biotherapeutics (SNSE) to Neutral

Oct 30, 2025 09:00AM Sensei Biotherapeutics discontinues drug development, explores sale

Oct 30, 2025 08:55AM Sensei Biotherapeutics (SNSE) Halted, News Pending

Oct 17, 2025 08:02AM Sensei Biotherapeutics reports clinical trial results for cancer drug

Oct 16, 2025 02:16PM Sensei Biotherapeutics (SNSE) halted on volatility

Aug 5, 2025 09:42AM Sensei Biotherapeutics (SNSE) PT Raised to $30 at H.C. Wainwright

Jun 13, 2025 07:30AM Sensei Biotherapeutics (SNSE) Announces 1:20 Reverse Share Split

Jun 2, 2025 06:39AM H.C. Wainwright Assumes Sensei Biotherapeutics (SNSE) at Buy

May 6, 2025 04:34PM Sensei Biotherapeutics, Inc. (SNSE) Misses Q1 EPS by 4c

Mar 28, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Sensei Biotherapeutics (SNSE)

Mar 27, 2025 04:05PM Sensei Biotherapeutics (SNSE) Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Nov 14, 2024 07:35AM Sensei Biotherapeutics, Inc. (SNSE) Tops Q3 EPS by 2c

Aug 6, 2024 08:58AM Sensei Biotherapeutics, Inc. (SNSE) Tops Q2 EPS by 1c